What Sponsors Should Expect During the First 90 Days of Working with a CRO
Selecting a clinical research organization (CRO) is an important milestone, but signing the contract is only the beginning.
The first 90 days of the relationship can set the tone for the entire clinical trial. This is when strategy begins turning into execution: goals are aligned, responsibilities are defined, study documents take shape, sites are evaluated, systems are prepared, and the operational foundation for enrollment is built.
For sponsors, especially those preparing for a first-in-human or pivotal study, this period can feel deceptively quiet. There may not be patients enrolling yet, but an enormous amount of work should be happening behind the scenes.
A strong CRO should bring structure, transparency, attention to detail, and experienced clinical project management to that process. Sponsors should know what’s happening, what comes next, where decisions are needed, and what could put the study timeline at risk.
What Those First 90 Days Should Look Like
1. Project Kickoff & Goal Alignment
A productive CRO relationship begins with more than a handoff of documents.
The kickoff meeting should bring together the sponsor, CRO leadership, clinical operations, regulatory, data management, biostatistics, and other relevant experts to establish a shared understanding of the study and its objectives.
Early discussions should address:
Study objectives and clinical development goals
Regulatory strategy and relevant FDA feedback
Intended regulatory claims
Key endpoints and follow-up requirements
Roles and responsibilities
Communication and escalation pathways
Major study milestones
Known risks, dependencies, and outstanding decisions
Sponsor expectations for reporting and CRO oversight
Start-up timeline planning
This alignment matters because clinical studies involve many interconnected workstreams. Decisions about the protocol can affect the database. Site requirements can influence enrollment assumptions. Regulatory feedback can change endpoints or follow-up. Vendor timelines can affect site activation.
Everyone needs to understand not only their individual responsibilities, but how their work fits into the larger study.
2. Building the Study Foundation
Once the team is aligned, one of the first priorities should be translating the clinical strategy into a realistic operational roadmap.
A detailed study startup Gantt chart should identify major activities, dependencies, owners, and target dates across the startup period.
Depending on the study, this may include:
protocol development,
document preparation,
regulatory submissions,
IRB activities,
vendor setup,
database development and validation,
site selection,
site contracting and budget negotiations, and
activation.
The timeline should represent more than the fastest theoretical route to enrollment—it should account for the actual work required to prepare a compliant, operationally sound study.
The CRO should also identify potential bottlenecks early and communicate them clearly. If one delayed decision could affect three downstream activities, the sponsor should know that before it becomes a timeline problem.
This is where experienced project management adds significant value: coordinating multiple workstreams so that the study progresses as one cohesive program rather than a collection of disconnected tasks.
3. Developing Essential Study Documents
Study startup requires extensive documentation, and developing those materials should be a major focus during the first 90 days.
The clinical protocol is central to this process. It establishes the study objectives, design, population, endpoints, procedures, follow-up, and data collection requirements that drive nearly every other aspect of the trial.
Protocol development should involve appropriate clinical, regulatory, statistical, operational, and physician expertise. The goal isn’t simply to produce a scientifically sound document, but to create a study that can be executed successfully at participating sites.
Once the protocol is sufficiently developed, other essential documents can move forward, including:
Case Report Forms (CRFs)
Informed Consent Forms (ICFs)
Monitoring Plan
Safety Management Plan
Data Management Plan
Statistical Analysis Plan, as appropriate
Other study-specific plans, manuals, and charters
These documents shouldn’t be developed in silos. CRFs, for example, need to capture the data required by the protocol and planned analyses. The monitoring strategy needs to reflect study risks and critical data. The safety plan needs to align with protocol requirements and regulatory expectations.
Attention to these connections helps prevent inconsistencies that otherwise may not become apparent until sites are activated or data are already being collected.
4. Site Selection & Startup
Choosing the right sites is about more than identifying investigators who are interested in participating.
Early in startup, the sponsor and CRO should finalize site selection criteria that reflect the actual needs of the study. Factors may include:
Investigator experience
Access to the target patient population
Realistic enrollment potential
Available infrastructure and staff
Experience with similar devices, therapies, or procedures
Competing clinical studies
Startup capabilities and expected timelines
The CRO can then use those criteria to identify, assess, and prioritize prospective sites.
As sites move forward, startup activities expand to qualification, budget and contract negotiations, essential document collection, regulatory and IRB requirements, and activation planning.
Strong CRO management keeps these activities visible to the sponsor so it’s clear which sites are progressing, which are stalled, why delays are occurring, and what action is required.
5. Regulatory & IRB Coordination
Regulatory and clinical activities should remain closely coordinated throughout startup.
Depending on the study and its stage of development, the first 90 days may include preparation or coordination of regulatory submissions, responses to agency feedback, IRB submissions, informed consent review, and collection of site-specific regulatory documentation.
Timing is critical. Regulatory requirements can affect the protocol, ICF, database, sites, and other study materials, so changes need to be communicated across workstreams quickly.
Sponsors should expect their CRO to help manage these dependencies rather than treating regulatory and operational activities as separate tracks.
6. Data Management & Monitoring Preparation
A clinical study needs to be ready to collect, review, and protect high-quality data before the first participant is enrolled.
During startup, data management activities should progress following protocol and CRF finalization. Once data requirements are sufficiently defined, database development can begin, followed by edit checks, user acceptance testing, validation, and other readiness activities.
At the same time, the Data Management Plan should establish how clinical data will be collected, reviewed, cleaned, queried, and managed throughout the study.
Monitoring preparation should also be well underway. The Monitoring Plan should define how study conduct, participant safety, protocol compliance, and data quality will be evaluated during execution.
These plans should reflect the actual protocol and study risks, not simply serve as standard templates.
7. Preparing for First Patient Enrollment
By the end of the initial startup period, the various pieces of the study should begin converging toward a common objective: enrollment readiness.
Before the first patient can be enrolled, sponsors and CROs need confidence that the necessary study infrastructure is in place.
Depending on the trial, readiness may include:
Protocol and required study documents finalized
Required regulatory and IRB approvals obtained
Sites qualified and activated
Contracts and budgets executed
EDC configured, validated and live
Monitoring, safety, and data management plans finalized
Study vendors contracted and trained
Required site training complete
Study materials and operational processes in place
This is why cohesion during the first 90 days matters so much. No single workstream determines whether a study is ready to enroll. The study moves forward when the individual components are coordinated and ready together.
8. How Proactive Communication Keeps Studies on Track
Sponsors should never have to wonder what their CRO is doing.
Regular communication is one of the clearest indicators of a strong CRO partnership. Weekly or bi-weekly meetings can provide visibility into study progress, upcoming milestones, risks, decisions, budgets, and action items.
But good communication involves more than providing status updates.
A strong CRO should be willing to raise concerns early, explain their potential impact, recommend solutions, and involve the right experts and management personnel when decisions are needed.
That means sponsors should expect:
Clear ownership of action items
Transparent milestone and timeline reporting
Early identification of risks and delays
Direct communication when assumptions change
Access to subject matter experts when needed
Appropriate involvement from CRO leadership
Collaborative problem-solving rather than reactive escalation
The sponsor-CRO relationship works best as a partnership. Both sides should understand the objectives, share information openly, make timely decisions, and remain accountable for moving the study forward.
What a Strong First 90 Days Should Accomplish
The first 90 days with a CRO should create more than a collection of completed tasks. They should establish the foundation for an organized, cohesive, and well-managed clinical trial.
By this point, sponsors should have greater clarity around the study roadmap, a detailed startup timeline, advancing or finalized study documentation, established site selection criteria, coordinated regulatory and IRB activities, data and monitoring infrastructure in development, and a clear path toward first patient enrollment.
Just as important, sponsors should feel confident in the partnership itself.
They should know who is managing the study, have access to the expertise needed to make informed decisions, understand where the program stands, and trust that potential problems will be communicated before they become major setbacks.
How NMCG Supports Clinical Trial Startup
At NMCG, clinical trial management combines strategic clinical and regulatory expertise with hands-on operational execution.
Our clinical, regulatory, biostatistics, data management, and project management experts work together to help sponsors move from study strategy through startup with attention to the details and dependencies that can determine whether a trial stays on track.
That integrated approach helps create cohesion across protocol development, study documentation, regulatory planning, site startup, data management, monitoring, and enrollment readiness.
Throughout the process, sponsors receive direct communication, transparent project management, and access to experienced experts and leadership.
A successful clinical trial requires more than completing a startup checklist. It requires a CRO partner that understands how every decision connects to the larger clinical and regulatory strategy.
Ready to plan your clinical trial roadmap?
Whether you're preparing to engage a CRO or getting ready to launch your next study, early planning
can help establish realistic expectations, identify risks, and create a clearer path to enrollment.
Schedule a no-cost consultation to discuss your clinical trial roadmap.
